Asset Details
Do you wish to reserve the book?
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
Do you wish to request the book?
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
2025
Overview
Blood biomarkers of Alzheimer’s disease (AD) are promising for dementia prediction, but their association with progression across intermediate stages of cognitive decline in the general population remains unclear. We followed 2148 dementia-free individuals from a Swedish population-based cohort for up to 16 years. Associations between baseline AD blood biomarkers and transitions between normal cognition, mild cognitive impairment (MCI), and dementia were examined. Lower amyloid-β42/40 ratio and higher phosphorylated-tau181 (p-tau181), p-tau217, total-tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were associated with faster progression from MCI to all-cause and AD dementia, with the strongest associations for NfL and p-tau217. Elevated NfL and GFAP were linked to reduced MCI reversion to normal cognition, whereas no biomarker was associated with MCI development from normal cognition. These findings show robust group-level associations and indicate that AD blood biomarkers may help stratify dementia risk at the MCI stage in the community.
Blood biomarkers of Alzheimer’s disease, including p-tau217, are linked with faster progression from mild cognitive impairment to dementia, supporting their potential for risk stratification at the stage of mild cognitive impairment in the community.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 82/1
/ Age
/ Aged
/ Alzheimer Disease - diagnosis
/ Amyloid
/ Amyloid beta-Peptides - blood
/ Anemia
/ Blood
/ Cognitive Dysfunction - blood
/ Cognitive Dysfunction - diagnosis
/ Dementia
/ Female
/ Glial fibrillary acidic protein
/ Glial Fibrillary Acidic Protein - blood
/ Humanities and Social Sciences
/ Humans
/ Male
/ Neurofilament Proteins - blood
/ Proteins
/ Science
/ Sweden
